CHL Medical Partners, an American venture capital firm, invests in biotechnology, molecular diagnostic, and medical device companies.
Business Model:
Revenue: $14.4M
Employees: 2-10
Address: 1055 Washington Blvd
City: Stamford
State: CT
Zip: 06901
Country: US
CHL Healthcare Partners is a venture capital firm that focuses on investing in healthcare companies.
Contact Phone:
+12033247700
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2007 | Spine Wave | Series D | 45M |
9/2010 | OpGen | Series B | 0 |
4/2000 | RxCentric | Series B | 14M |
6/2001 | Protometrix | Seed Round | - |
10/2004 | GeneOhm Sciences | Series C | 12M |
8/2014 | Mevion Medical Systems | Private Equity Round | 0 |
6/2013 | Mevion Medical Systems | Private Equity Round | 0 |
6/2007 | BioRelix | Series A | 25.8M |
6/2003 | Eunoe | Venture Round | 40M |
12/2005 | Oculir | Series A | 7.3M |
10/2007 | Mevion Medical Systems | Series C | 6.9M |
6/2009 | VaxInnate | Series D | 30M |
10/2009 | Vertos Medical | Series D | 0 |
12/2000 | Molecular Staging | Series D | 41.3M |
1/2004 | Threshold Pharmaceuticals | Series B | 41M |
1/2009 | Mevion Medical Systems | Venture Round | 33M |
12/1990 | ICOS Corporation | Venture Round | - |
2/2006 | Spine Wave | Series C | 36.5M |
9/2006 | Cantex Pharmaceuticals | Series B | 19M |
9/2011 | Valeritas | Series C | 150M |
6/2007 | Millennium Pharmacy Systems | Venture Round | 40M |
1/2008 | North American Scientific | Venture Round | 15.5M |
1/2003 | Lumend | Series D | 23.2M |
12/2005 | Resolvyx Pharmaceuticals | Series A | 17M |
1/2008 | POINT Biomedical | Private Equity Round | 0 |
7/2002 | RxCentric | Series D | 3M |
7/2001 | RxCentric | Series C | 5M |
3/2007 | Ascend Health | Series B | 20.1M |
6/2014 | Vascular Pathways | Debt Financing | 0 |
11/2010 | Ambra Health | Series A | 0 |
5/2012 | Ambra Health | Series B | 0 |
9/2005 | Amicus Therapeutics | Series C | 55M |
3/2004 | VaxInnate | Series B | 23.1M |
10/2006 | VaxInnate | Series C | 40M |
1/2012 | Mevion Medical Systems | Venture Round | 0 |
1/2005 | GeneOhm Sciences | Series C | 0 |
10/2009 | PrimeraDx (Primera Biosystems) | Series C | 20M |
9/2007 | OpGen | Venture Round | 0 |
5/2004 | Amicus Therapeutics | Series B | 31M |
9/2006 | Amicus Therapeutics | Series D | 60M |
5/2000 | Lifespire | Venture Round | - |
7/2008 | Vertos Medical | Series C | 12M |
11/2010 | Vascular Pathways | Series B | 0 |
7/2002 | Amicus Therapeutics | Series A | 2M |
3/2012 | OpGen | Series C | 0 |
11/2007 | BIKAM Pharmaceuticals | Series A | 11M |
5/2002 | VaxInnate | Series A | 1M |
7/2012 | CareWell Urgent Care | Series A | 0 |
8/2014 | Mevion Medical Systems | Private Equity Round | 0 |
6/2014 | Vascular Pathways | Debt Financing | 0 |
6/2013 | Mevion Medical Systems | Private Equity Round | 0 |
7/2012 | CareWell Urgent Care | Series A | 0 |
5/2012 | Ambra Health | Series B | 0 |
3/2012 | OpGen | Series C | 0 |
1/2012 | Mevion Medical Systems | Venture Round | 0 |
9/2011 | Valeritas | Series C | 0 |
11/2010 | Ambra Health | Series A | 0 |
11/2010 | Vascular Pathways | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|